Researchers at the Immaculate Dermopathic Institute (IDI-IRCCS, Rome) are using Bio-Plex technology in developing new anti-proliferation molecules and markers at the early stages of melanoma pathology. Dr Antonio Facchiano discusses how Bio-Plex has expedited the lab’s research.

Previous post

New and Improved CFX Manager™ Software for Real-Time PCR Data Acquisition and Analysis

Next post

High Sensitivity of Bio-Plex® Multiplex System is Key in Study for Novel Melanoma Therapeutics